Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes

By  

Current Diabetes Reviews, Vol. 6, Iss. 4, 2010-07 ,pp. : 191-200

Bentham Science Publishers

Access to resources Recommend Favorite

GLP-1 receptor agonists in the treatment of Type 2 diabetes

By Ahrén Bo  

Diabetes Management, Vol. 3, Iss. 5, 2013-09 ,pp. : 401-413

Future Medicine

Access to resources Recommend Favorite

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome

By  

Current Vascular Pharmacology, Vol. 15, Iss. 3, 2017-04 ,pp. : 218-229

Bentham Science Publishers

Access to resources Recommend Favorite

Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes

By Setji Tracy   Feinglos Mark  

Expert Review of Endocrinology and Metabolism, Vol. 8, Iss. 3, 2013-05 ,pp. : 229-238

Informa Healthcare

Access to resources Recommend Favorite

Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)

By  

Current Vascular Pharmacology, Vol. 14, Iss. 5, 2016-09 ,pp. : 469-473

Bentham Science Publishers

Access to resources Recommend Favorite